REGENXBIORGNX
Recorded

REGENXBIO Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration32 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Annabel SamimyManaging Director

All right. Good morning, everyone, and thank you for coming to the Regenxbio session. Regenxbio, as you know, is a very solid, vertically integrated gene therapy company focused on muscular, rare muscular diseases, as well as large retinal diseases. So, a two-track approach. With us today is Curran Simpson, CEO, Steve Pakola, Chief Medical Officer, and Ram Palanki, who is Chief Commercial Officer, as you are soon transitioning to commercial, so you are going to be a very important person up here, Ram. First, why don't we get a good overview of where you stand today?

Annabel SamimyManaging Director

Level the playing field for everyone, and then we can launch into questions.

Curran SimpsonCEO

Great. When I was riding up on Amtrak, I was thinking about the first RGX-314 experiments I saw coming out of Jim Wilson's lab in Pennsylvania, and here we are 10-plus years later.

Curran SimpsonCEO

Just weeks away from our top-line data. So it's an exciting time. These are the largest gene therapy studies ever conducted, and we are super excited to work with AbbVie on this program. They've been with us for about three and a half years to sort of unveil the results. I think we are really confident in the data. We've spent a lot of time, Steve can attest, in phase I/II development, finding the ideal doses for a pivotal program. We did a really comprehensive pharmacodynamic study to look at our commercial process in a clinical setting, and I think that's all set the table for these two large studies to read out, and in a great way, on top of each other. So we will have data in a joint release soon before the end of this year with AbbVie announcing the top-line results.

Curran SimpsonCEO

Yeah. Very excited. Confident and excited, and all the things that go into drug development.

Curran SimpsonCEO

It has been a great ride, and we are looking forward to seeing how that data looks in a few weeks.

Annabel SamimyManaging Director

Great. Why don't we talk about this program a little? You have mentioned multiple times it is the largest gene therapy trial. They are the largest gene therapy trials, because there are two of them.

Annabel SamimyManaging Director

Yeah ever conducted. Maybe you can just lay that out for us, explain to us, or describe exactly how expansive they are, what you are looking for with the primary endpoints, what are the benchmarks that people should be looking at?

Curran SimpsonCEO

Great. Yeah, maybe I will let Steve walk through the design.

Steve PakolaCMO

Sure. Thanks, Annabel. Yes, this is the largest gene therapy program ever conducted, but it is also important to point out that it is also the most comprehensive program, and that really goes for the overall program, including the initial clinical studies, including the pharmacodynamic study that Curran mentioned. I think another key point is these trials had the benefit of multiple prior studies from which to make dose selection, to make decisions on all the different inclusion/exclusion criteria, retreatment criteria, where we had an opportunity to have very good data from phase II and to really replicate all these different variables so that we do not have that risk of not replicating what we saw in our prior studies. So, what do we want to show?

Steve PakolaCMO

We, of course, want to show good visual acuity results, and that is the primary endpoint, but we also, of course, need to show that you can achieve that even with a dramatic reduction in treatment burden, and also sustain disease activity. So that speaks to the endpoints that we care about. The basic design is previously treated wet AMD patients with a history up to four years of treatment. In terms of comprehensive, the key thing here is because of what we had seen previously and really the route of administration that we chose, subretinal, we are able to get to doses without any immune-mediated safety issues where we believe that we can treat tougher-to-treat patients.

Steve PakolaCMO

Our inclusion criteria allow patients who do have a higher treatment burden in a way that other programs don't have that flexibility to include. That's a key aspect because that's what clinicians want to treat.

Steve PakolaCMO

We hear that over and over again. The biggest unmet need for them and their patients is these tougher-to-treat patients, and that's ideally who they want to treat with a one-time gene therapy. So those patients come in the trial. In these two trials, it's over 1,300 patients. The basic design is really tried and true, so there's no regulatory risk to the approach if we can meet the primary endpoint. Its primary endpoint is non-inferiority to on-label anti-VEGF.

Steve PakolaCMO

In one treatment arm, it's monthly LUCENTIS, and in the other, it's loading doses plus every other month of aflibercept. We also have the benefit to increase probability of success that we were able to go with two arms of sura-vec. We have a low dose and a high dose. Primary endpoint is non-inferiority on change from baseline best corrected visual acuity at 54 weeks, highly no regulatory risk there. We have the key secondary endpoints of reduction in injection burden, where again, we've seen very good response in all our prior studies. Also the goal to have a reasonable proportion of those patients have need for no injections over the year. Another key one is you want to see disease stability anatomically. We also want to see stability or improvement on retinal thickness measured by OCT.

Steve PakolaCMO

Lot of work. Yeah from us and AbbVie, but almost there.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day